Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab OA Arthroplasty Specimen Study
NCT03949673Phase 2
Key facts
- Status
- Terminated
- Start
- Apr 2019
- Primary completion
- Aug 2020
- Countries
- 3
- Sponsor
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies
- Drugs
- fasinumab
- Conditions
- osteoarthritis (OA)
01
Overview
Phase 2, randomised, double-blind trial of fasinumab in osteoarthritis (OA), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Number of Participants by Degree of Synovial Lymphocytic Inflammation, Number of Participants by Degree of Cartilage Loss and 1 more. Started Apr 2019; status: terminated.
02
Design
1 arm- Study design
- RandomizedDouble-blind
Arthroplasty Cohort
Patients from parent studies undergoing knee or hip arthroplasty.
03
Who it enrols
Patients previously randomized to specific fasinumab parent studies (NCT02683239, NCT03161093, NCT03304379) who are planning a knee or hip arthroplasty.
04
Endpoints
Primary
Number of Participants by Degree of Synovial Lymphocytic Inflammation
Number of Participants by Degree of Cartilage Loss
Number of Participants by Degree of Bony Changes
Beyond the preview
Go deeper on NCT03949673.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03949673.